Enterprise Value

-239M

Cash

373.3M

Avg Qtr Burn

N/A

Short % of Float

7.33%

Insider Ownership

14.22%

Institutional Own.

88.45%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Relyvrio (AMX0035) Details
Amyotrophic lateral sclerosis

Approved

Update

AMX0035 Details
Progressive supranuclear palsy

Phase 3

Data readout

Relyvrio (AMX0035) Details
Amyotrophic lateral sclerosis

Phase 3

Update

Avexitide Details
Hyperinsulinism, Post-Bariatric Hypoglycemia, Congenital Hyperinsulinism

Phase 3

Initiation

AMX0035 Details
Wolfram syndrome

Big Mover™

Susp. Mover™

Phase 2

Data readout

AMX0035 Details
Alzheimer's disease

Phase 2

Update

AMX0114 Details
Amyotrophic lateral sclerosis

Phase 1

Initiation